Unknown

Dataset Information

0

18?-Glycyrrhetinic Acid Inhibits Osteoclastogenesis In Vivo and In Vitro by Blocking RANKL-Mediated RANK-TRAF6 Interactions and NF-?B and MAPK Signaling Pathways.


ABSTRACT: Bone metabolism is determined by a delicate balance between bone resorption by osteoclasts and bone formation by osteoblasts. The imbalance due to over-activated osteoclasts plays an important role in various diseases. Activation of NF-?B and MAPK signaling pathways by receptor activator of nuclear factor -?B ligand (RANKL) is vital for osteoclastogenesis. Here, we for the first time explored the effects of 18?-glycyrrhetinic acid (18?-GA), a pentacyclic triterpenoid found in the Glycyrrhiza glabra L roots, on RANKL-induced osteoclastogenesis, osteoclast functions and signaling pathways in vitro and in vivo. In bone marrow monocytes (BMMs) and RAW264.7 cells, 18?-GA inhibited osteoclastogenesis, decreased expression of TRAP, cathepsin K, CTR and MMP-9, blocked actin ring formation and compromised osteoclasts functions in a dose-dependent manner at an early stage with minimal effects on osteogenic and adipogenic differentiation of bone marrow mesenchymal stem cells (BMSCs). For underlying molecular mechanisms, 18?-GA inhibited RANKL-induced phosphorylation of p65, p50, and I?B, blocked p65 nuclear translocation and decreased the DNA-binding activity of NF-?B. Besides, 18?-GA inhibited the activation of the MAPK pathways. Co-immunoprecipitation showed that 18?-GA treatment blocked RANK-TRAF6 association at an upstream site. In vivo, 18?-GA treatment inhibited ovariectomy-induced osteoclastogenesis and reduced bone loss in mice. Overall, our results demonstrated that 18?-GA inhibited RANKL-induced osteoclastogenesis by inhibiting RANK expression in preosteoclasts and blocking the binding of RANK and TRAF6 which lead to the inhibition of NF-?B and MAPK signaling pathways. 18?-GA is a promising novel candidate in the treatment of osteoclast-related diseases such as postmenopausal osteoporosis.

SUBMITTER: Chen X 

PROVIDER: S-EPMC6019442 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

altmetric image

Publications

18β-Glycyrrhetinic Acid Inhibits Osteoclastogenesis <i>In Vivo</i> and <i>In Vitro</i> by Blocking RANKL-Mediated RANK-TRAF6 Interactions and NF-κB and MAPK Signaling Pathways.

Chen Xiao X   Zhi Xin X   Yin Zhifeng Z   Li Xiaoqun X   Qin Longjuan L   Qiu Zili Z   Su Jiacan J  

Frontiers in pharmacology 20180620


Bone metabolism is determined by a delicate balance between bone resorption by osteoclasts and bone formation by osteoblasts. The imbalance due to over-activated osteoclasts plays an important role in various diseases. Activation of NF-κB and MAPK signaling pathways by receptor activator of nuclear factor -κB ligand (RANKL) is vital for osteoclastogenesis. Here, we for the first time explored the effects of 18β-glycyrrhetinic acid (18β-GA), a pentacyclic triterpenoid found in the <i>Glycyrrhiza  ...[more]

Similar Datasets

| S-EPMC7205840 | biostudies-literature
| S-EPMC6933417 | biostudies-literature
| S-EPMC8573428 | biostudies-literature
| S-EPMC8236062 | biostudies-literature
| S-EPMC7754000 | biostudies-literature
| S-EPMC8178255 | biostudies-literature
| S-EPMC7849192 | biostudies-literature
| S-EPMC7995782 | biostudies-literature
| S-EPMC5003737 | biostudies-literature
| S-EPMC8237092 | biostudies-literature